FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2023.
Commission File Number: 001-40627
SOPHiA GENETICS SA
(Exact name of registrant as specified in its charter)
La Pièce 12
CH-1180 Rolle
Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOPHIA GENETICS SA

Date: August 14, 2023

By: /s/ Daan van Well
Name: Daan van Well
Title: Chief Legal Officer
<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Informative slides SOPHiA GENETICS for UBS Conference dated August 15, 2023</td>
</tr>
</tbody>
</table>
Democratizing Data-Driven Medicine

Ross Muken
Chief Financial Officer & Chief Operating Officer

August 15, 2023
Cautionary Notices

This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this presentation. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this presentation to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

No offer to sell or buy
This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Other material information
This presentation does not contain all material information about SOPHiA GENETICS SA and its subsidiaries. No representations or warranties (expressed or implied) are made regarding the completeness of the information contained in this presentation. Refer to our Securities and Exchange Commission filings for additional information about us.

Market and industry data
This presentation contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Our estimates of addressable market (or similar concepts) are primarily based on epidemiological data, including incidence and prevalence estimates of addressable populations, as well as a range of price assumptions for our products taking into account differences in panel sizes, which may change over time. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. While we are not aware of any misstatements regarding the industry, market and competitive position data presented herein, these data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty.

Research use only
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this presentation is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
Snapshot of SOPHiA GENETICS

We are a category defining software company on a mission to Democratize Data-Driven Medicine.

The information on this slide is as of 06/30/2023.
The Emergence of the Cloud and AI have transformed countless industries.

**BUT, Healthcare is lagging.**
### Healthcare Data is Complex, Siloed and Diverse

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>First line treatment</th>
<th>Monitoring</th>
<th>Progression</th>
<th>2nd line treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>GP Visit</td>
<td>Medical Oncologist</td>
<td>Radiologist</td>
<td>Biologist</td>
<td>Tumour Board</td>
</tr>
<tr>
<td>Clinical</td>
<td>Symptoms</td>
<td>First line &amp; personal history</td>
<td>Imaging</td>
<td>Follow-up Visits</td>
</tr>
<tr>
<td></td>
<td>Coughing</td>
<td>Smoking history</td>
<td>Imaging</td>
<td>CT scan</td>
</tr>
<tr>
<td></td>
<td>Shortness of breath</td>
<td>Performance status</td>
<td>Imaging</td>
<td>PET/CT scan</td>
</tr>
<tr>
<td>Imaging</td>
<td>Chest X-ray</td>
<td>Chest CT/RI scan</td>
<td>Imaging</td>
<td>CT scan</td>
</tr>
<tr>
<td>Histopathology</td>
<td>PET/CT scan</td>
<td>Tissue biopsy</td>
<td>Imaging</td>
<td>PET/CT scan</td>
</tr>
<tr>
<td>Genomics</td>
<td>NGS</td>
<td>Genomic DNA</td>
<td>Imaging</td>
<td>PET/CT scan</td>
</tr>
<tr>
<td>Lab tests</td>
<td>Complete blood count</td>
<td>Biochemistry</td>
<td>Imaging</td>
<td>PET/CT scan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Tumour Board</th>
<th>First Evaluation</th>
<th>Treatment Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment decisions</td>
<td>PS</td>
<td>PS</td>
<td>PS</td>
</tr>
<tr>
<td>Side effects</td>
<td>Quality of life</td>
<td>PS</td>
<td>PS</td>
</tr>
<tr>
<td>Treatment decision</td>
<td>PD</td>
<td>PD</td>
<td>PD</td>
</tr>
</tbody>
</table>

**Notes:**
- PD: Progression detected.
- N/A: Not applicable.

**Table Legend:**
- BC: Blood count.
- Hb: Haemoglobin.
- RBC: Red blood cells.
- WBC: White blood cells.
- NGS: Next-generation sequencing.
- NGS: Liquid biopsy.
- NAD: Not applicable.
- NGS: Liquid biopsy.
- RET: Rearranged during transfection.
Creating Network Effects in Healthcare is Difficult given non-standardized methods and sensitive data
Significantly Important for Key Diseases

driven by genomic alterations

Cancer
>25 Million New Cancer Cases per Year

Rare Diseases
~5% of the global population suffers from a Rare Disease

1. by 2040, 2. https://www.rarediseasesinternational.org/
New Data Modalities Bring Objectivity into human biology and diseases
Applying AI to Genomic Data
HRD example for PARP inhibitors

FFPE DNA Tumor Sample → WGS Library → Captured Library (HRD genes) → Load Flowcell → Variant calling

Whole genome low-coverage profile

Low-pass WGS coverage → Feature extraction → Relevant features → Classifier

Output

SOPHiA DDM®

CAUSE
Germline and somatic variants in HRD genes

EFFECT
SOPHiA GENETICS
Genomic Integrity Index

© SOPHiA GENETICS 2023
Applying AI to Multimodal Data
NSCLC example for Immunotherapy

Image processing
- Source image
- Segmentation model
- 3D segmentation
- Feature extraction
  - Shape
  - Intensity
  - Texture
  - 200+ radiomics features
    (IBSI compliant)

Multimodal data aggregation
- Radiomics
- Genomics
- Clinical
- Biological

Outcome prediction model
- Missing data imputation
- Feature selection
- Classification model
- Calibration

Model interpretability

Patient-specific prediction

© SOPHiA GENETICS 2023
Our Ability to Deliver Healthcare Solutions
Built on collective intelligence from our global network

Discovery
Apply benefits of proprietary AI/ML to late-stage discovery phases

Development
Comprehensive suite of applications backed by AI-based algorithms to aid in harmonization and reporting

Deployment
Expand access to genomic applications (both internal or 3rd party) by leveraging our global network
Transforming Healthcare through Key Strategic Collaborations

- Generate robust insights
- Break data silos
- Create a collective intelligence
- Accelerate adoption of precision medicine
Growing with our Customer’s Volume
via a consumption based SaaS model

University Hospitals
Comprehensive Cancer Centers
Specialty Labs
Central Labs

Upload Data

Proprietary Algorithms and patented technologies

MINKA
NINGER®
PEPPER®
SUSKAT®
SLIMIN®
MUSTARD®

Consumption based model

Interpret Data

Targeted Clinical Outcomes

Clinical Reporting

FN 1: Patents pending.
A Look into a Customer’s Expansion Journey
as volume and the number of applications increase

JAN 2019
- $8K revenue
- 5 applications
- 200 analyses

END 2019
- $160K revenue
- 7 applications
- 3,000 analyses

END 2020
- $270K revenue
- 7 applications
- 3,200 analyses

END 2021
- $650K revenue
- 9 applications
- 6,100 analyses

2022
- $1.1M revenue
- 9 applications
- 9,300 analyses

Successful partnership founded on collaboration, loyalty, and trust

Since 2019
91% Revenue CAGR
47% Analysis CAGR
100% of somatic business converted
Importantly, Customer Growth Accelerates as they get Larger

Customer count by annual revenue contribution:

- $200K+
- $150K-200K
- $100K-150K
- $50-100K
- <$50K+

Note: Based on recurring platform customers. FN 1: Represents CAGR of total tier revenue of customers with $100K+ in revenue and CAGR of total tier revenue of customers with $0-$100K in revenue. © SOPHiA GENETICS 2023
Key Financial Metrics

750+
Total customers (1)

430+
Core Genomics customers (2)

1.4 million+
Genomic Profiles Analyzed (3)

~78,000+
Genomic profiles analyzed in 2Q 2023 (1)

30% - 35%
2023 constant currency ex COVID revenue growth guidance as of August 8, 2023 (2,4)

30%
2Q2023 constant currency ex COVID revenue growth (3)

67% | 70%
Q2 2023 IFRS gross profit margin | adjusted gross profit margin (3)

~$149M
Cash, cash equivalents, & term deposits (2)

FN 1: Represents statistic as of 06/30/2023. FN 2: The Company is unable to provide a reconciliation of forward-looking constant currency revenue growth excluding COVID-19-related revenue to Revenue, the most comparable IFRS financial measure, due to the inherent difficulty in forecasting and quantifying the impact of foreign currency translation. FN 3: Please refer to appendix for non-IFRS reconciliation. FN 4: Represents financial outlook as of August 8, 2023. This presentation does not represent an update or affirmation of previously disclosed guidance. FN 5: Represents statistic as of 06/30/2023.
Thank You
# Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin

for the Three Months Ended June 30, 2023

<table>
<thead>
<tr>
<th>Amounts in USD thousands (unaudited)</th>
<th>Three months ended June 30, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>$15,054</td>
</tr>
<tr>
<td><strong>Cost of revenue</strong></td>
<td>(5,007)</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>$10,047</td>
</tr>
<tr>
<td>Amortization of capitalized research and development expenses (1)</td>
<td>496</td>
</tr>
<tr>
<td><strong>Adjusted gross profit</strong></td>
<td>$10,543</td>
</tr>
<tr>
<td><strong>Gross profit margin</strong></td>
<td>67%</td>
</tr>
<tr>
<td>Amortization of capitalized research and development expenses (1)</td>
<td>3%</td>
</tr>
<tr>
<td><strong>Adjusted gross profit margin</strong></td>
<td>70%</td>
</tr>
</tbody>
</table>

FN 1: Please refer to appendix for non-IFRS reconciliation
### Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth and Constant Currency Revenue Growth Excluding COVID-19-Related Revenue

(Amounts in USD thousands)

<table>
<thead>
<tr>
<th></th>
<th>2022 Q2</th>
<th>2023 Q2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reported Revenue</strong></td>
<td>$11,667</td>
<td>$15,054</td>
</tr>
<tr>
<td>Y-o-Y Growth</td>
<td></td>
<td>29%</td>
</tr>
<tr>
<td><strong>Current Period Constant Currency Impact</strong></td>
<td>(202)</td>
<td></td>
</tr>
<tr>
<td><strong>Constant Currency Revenue</strong></td>
<td>$11,667</td>
<td>$14,852</td>
</tr>
<tr>
<td>Y-o-Y Growth</td>
<td></td>
<td>27%</td>
</tr>
<tr>
<td>COVID-19 Revenue</td>
<td>(292)</td>
<td>(72)</td>
</tr>
<tr>
<td>Constant Currency Impact on COVID-19 Revenue</td>
<td></td>
<td>(8)</td>
</tr>
<tr>
<td><strong>Constant Current Revenue Excluding COVID-19 Revenue</strong></td>
<td>$11,375</td>
<td>$14,772</td>
</tr>
<tr>
<td>Y-o-Y Growth</td>
<td></td>
<td>30%</td>
</tr>
</tbody>
</table>
(1) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives.
Consistent Growth in Analysis Volume
accelerated momentum of analysis volume conducted on our platform in 1H 2023

Note: Includes analysis volume from all Core Genomics Customers using dry lab, bundle access, and integrated access models.